Market Closed -
OTC Markets
12:32:01 24/04/2024 am IST
|
5-day change
|
1st Jan Change
|
0.0001
USD
|
0.00%
|
|
0.00%
|
-99.76%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
24.41
|
3.493
|
12.07
|
59.48
|
60.97
|
9.041
|
Enterprise Value (EV)
1 |
25.05
|
1.696
|
5.313
|
57.34
|
44.78
|
8.253
|
P/E ratio
|
-
|
-
|
-0.23
x
|
-2.95
x
|
-18.9
x
|
-0.28
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.82
x
|
1.07
x
|
2.18
x
|
2.17
x
|
1
x
|
0.35
x
|
EV / Revenue
|
4.94
x
|
0.52
x
|
0.96
x
|
2.09
x
|
0.73
x
|
0.32
x
|
EV / EBITDA
|
-1.22
x
|
-0.07
x
|
-0.24
x
|
-3.99
x
|
-50.9
x
|
-0.27
x
|
EV / FCF
|
-1.9
x
|
-0.12
x
|
-0.34
x
|
-3.89
x
|
22.7
x
|
-0.89
x
|
FCF Yield
|
-52.5%
|
-802%
|
-291%
|
-25.7%
|
4.4%
|
-112%
|
Price to Book
|
-
|
1.31
x
|
1.4
x
|
2.51
x
|
1.63
x
|
1.02
x
|
Nbr of stocks (in thousands)
|
3.91
|
13.5
|
141
|
447
|
561
|
569
|
Reference price
2 |
6,245
|
258.0
|
85.80
|
133.2
|
108.6
|
15.90
|
Announcement Date
|
28/03/18
|
29/03/19
|
27/03/20
|
31/03/21
|
05/04/22
|
17/04/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
5.069
|
3.25
|
5.529
|
27.46
|
61.25
|
25.86
|
EBITDA
1 |
-20.6
|
-23.46
|
-22.13
|
-14.38
|
-0.879
|
-30.33
|
EBIT
1 |
-21.17
|
-24.26
|
-23.06
|
-15.47
|
-2.409
|
-31.98
|
Operating Margin
|
-417.76%
|
-746.35%
|
-417.05%
|
-56.33%
|
-3.93%
|
-123.69%
|
Earnings before Tax (EBT)
1 |
-21.61
|
-24.57
|
-25.14
|
-17.81
|
-2.699
|
-32.21
|
Net income
1 |
-21.61
|
-24.57
|
-25.14
|
-17.81
|
-2.824
|
-32.09
|
Net margin
|
-426.42%
|
-755.98%
|
-454.69%
|
-64.84%
|
-4.61%
|
-124.09%
|
EPS
|
-
|
-
|
-366.8
|
-45.11
|
-5.734
|
-56.78
|
Free Cash Flow
1 |
-13.16
|
-13.61
|
-15.48
|
-14.75
|
1.971
|
-9.222
|
FCF margin
|
-259.58%
|
-418.73%
|
-280.01%
|
-53.72%
|
3.22%
|
-35.66%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/03/18
|
29/03/19
|
27/03/20
|
31/03/21
|
05/04/22
|
17/04/23
|
Fiscal Period: December |
2021 Q1
|
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
---|
Net sales
1 |
-
|
12.05
|
17.47
|
13.93
|
19.94
|
10.61
|
5.587
|
-10.28
|
0.673
|
0.589
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-1.748
|
0.5016
|
-2.776
|
-2.707
|
-5.097
|
-5.577
|
-18.6
|
-
|
-
|
Operating Margin
|
-
|
-14.51%
|
2.87%
|
-19.93%
|
-13.57%
|
-48.04%
|
-99.82%
|
180.88%
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-1.827
|
0.427
|
-2.846
|
-2.768
|
-5.252
|
-5.545
|
-18.65
|
-
|
-
|
Net income
|
2.599
|
-1.827
|
0.427
|
-2.971
|
-2.768
|
-5.252
|
-5.545
|
-18.52
|
-
|
-
|
Net margin
|
-
|
-15.17%
|
2.44%
|
-21.33%
|
-13.88%
|
-49.5%
|
-99.25%
|
180.09%
|
-
|
-
|
EPS
|
5.700
|
-15.30
|
0.9000
|
-5.400
|
-4.800
|
-9.300
|
-9.900
|
-32.70
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/05/21
|
16/08/21
|
15/11/21
|
06/04/22
|
23/05/22
|
10/11/22
|
21/11/22
|
17/04/23
|
10/05/23
|
14/08/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
0.64
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
1.8
|
6.76
|
2.14
|
16.2
|
0.79
|
Leverage (Debt/EBITDA)
|
-0.0312
x
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-13.2
|
-13.6
|
-15.5
|
-14.8
|
1.97
|
-9.22
|
ROE (net income / shareholders' equity)
|
-2,211%
|
-1,133%
|
-353%
|
-102%
|
-9.23%
|
-138%
|
ROA (Net income/ Total Assets)
|
-177%
|
-188%
|
-109%
|
-29.7%
|
-2.79%
|
-43.8%
|
Assets
1 |
12.21
|
13.07
|
23.1
|
60.03
|
101.2
|
73.27
|
Book Value Per Share
|
-
|
197.0
|
61.40
|
53.10
|
66.70
|
15.60
|
Cash Flow per Share
|
-
|
222.0
|
51.00
|
32.20
|
51.40
|
22.70
|
Capex
1 |
1.4
|
0.15
|
0.74
|
0.87
|
1.57
|
0.81
|
Capex / Sales
|
27.62%
|
4.47%
|
13.3%
|
3.16%
|
2.57%
|
3.12%
|
Announcement Date
|
28/03/18
|
29/03/19
|
27/03/20
|
31/03/21
|
05/04/22
|
17/04/23
|
|
1st Jan change
|
Capi.
|
---|
| -99.76% | 262 | | +0.89% | 12.8B | | -10.29% | 7.61B | | -1.16% | 4.51B | | +5.74% | 4.49B | | -50.70% | 3.3B | | +12.21% | 2.73B | | -16.13% | 2.02B | | -11.50% | 1.73B | | -5.02% | 1.64B |
Diagnostic & Testing Substances
|